 November 23, 2017 - By Marguerite Chambers Raymond James Trust decreased its stake in Glaxo Smithkline Sponsored Plc (GSK) by 35.92% based on its latest 2017Q2 regulatory filing with the SEC. Raymond James Trust sold 47,510 shares as the company’s stock rose 5.47% with the market. The institutional investor held 84,756 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $3.66M, down from 132,266 at the end of the previous reported quarter. Raymond James Trust who had been investing in Glaxo Smithkline Sponsored Plc for a number of months, seems to be less bullish one the $85.41B market cap company. The stock increased 0.66% or $0.23 on November 22, reaching $35.06. About 4.22M shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 23, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.First City Capital Management Inc increased its stake in Sanofi Aventis (SNY) by 42.08% based on its latest 2017Q2 regulatory filing with the SEC. First City Capital Management Inc bought 11,370 shares as the company’s stock rose 14.25% with the market. The institutional investor held 38,389 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $1.84M, up from 27,019 at the end of the previous reported quarter. First City Capital Management Inc who had been investing in Sanofi Aventis for a number of months, seems to be bullish on the $114.79 billion market cap company. The stock increased 1.29% or $0.58 on November 22, reaching $45.37. About 968,722 shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since November 23, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.Among 11 analysts covering Sanofi-aventis Sa (NYSE:SNY), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Sanofi-aventis Sa had 20 analyst reports since October 15, 2015 according to SRatingsIntel. Barclays Capital upgraded the stock to “Equal-Weight” rating in Wednesday, November 15 report. JP Morgan maintained Sanofi SA (ADR) (NYSE:SNY) on Friday, April 21 with “Neutral” rating. Berenberg downgraded Sanofi SA (ADR) (NYSE:SNY) on Thursday, May 11 to “Hold” rating. The company was downgraded on Friday, April 7 by HSBC. On Thursday, May 12 the stock rating was upgraded by Barclays Capital to “Overweight”. On Friday, September 23 the stock rating was initiated by Piper Jaffray with “Neutral”. The rating was upgraded by Morgan Stanley on Thursday, October 15 to “Overweight”. Cowen & Co maintained Sanofi SA (ADR) (NYSE:SNY) rating on Friday, October 13. Cowen & Co has “Hold” rating and $52.0 target. The firm earned “Buy” rating on Thursday, September 8 by Berenberg. As per Monday, November 7, the company rating was initiated by Goldman Sachs.More news for Sanofi SA (ADR) (NYSE:SNY) were recently published by: Benzinga.com, which released: “The Pullback In Sanofi Is A Buying Opportunity, Says Argus” on September 01, 2017. Investorplace.com‘s article titled: “5 Reasons Why Sanofi SA (ADR) (SNY) is a Good Stock to Buy Now” and published on April 12, 2017 is yet another important article.Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 14. They expect $0.64 EPS, down 1.54% or $0.01 from last year’s $0.65 per share. GSK’s profit will be $1.56B for 13.70 P/E if the $0.64 EPS becomes a reality. After $0.85 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.71% negative EPS growth.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.